Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata

Comparative Efficacy of Tacrolimus 0.1% and Clobetasol Propionate 0.05% in the Treatment of Alopecia Areata

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05885269

Enrollment

Registered

2023-06-01

Start date

2022-11-01

Completion date

2023-04-30

Last updated

2023-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alopecia Areata

Brief summary

Methodology: The 70 patients of age 20 to 50 years presented to the out-patient department of CMH Abbottabad suffering from alopecia areata were enrolled. The non-probability consecutive sampling technique was used. Patient in group-A applied clobetasol propionate 0.05% twice daily, whereas Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months. The Patients were assessed at baseline, 4th weeks, 8th week and 12th week after treatment of each session. Hair loss was calculated from SALT score at presentation and on follow-up after 3 months. The degree of response was assessed on the basis of hair re-growth as excellent (\>75% re-growth), Marked (51-75% re-growth), moderate (26-50% re-growth), or slight (≤25% re-growth). To determine statistical significance χ2-square test, taking p-value \<0.05 as significant, was used.

Interventions

DRUGGroup A applied topical Clobetasol Propionate

Patient in group-A applied clobetasol propionate 0.05% twice daily for upto 03 months

DRUGGroup B applied topical Tacrolimus

Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 50 Years

Healthy volunteers

Inclusion criteria

* Patients age 20 to 50 years * Both male and female * Duration of illness less than 2 months * those who never received any treatment before

Exclusion criteria

* Patients having duration of alopecia greater than 2 months * Atypical alopecia areata i.e., Alopecia universalis etc * Hypersensitivity history to topical corticosteroids or tacrolimus * patients taking any systemic immune suppression * pregnancy/lactation

Design outcomes

Primary

Measure	Time frame	Description
The degree of response was assessed on The basis of hair regrowth as excellent, marked, moderate or slight.	6 months	The degree of response was assessed on the basis of hair regrowth as excellent (\>75% regrowth), marked (51-75% regrowth), moderate (26-50% regrowth), or slight (≤25% regrowth)

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026